Summary of Key Information:

Reporting Period: Quarter and Financial Year ended 31st March 2026

Nature of Filing / Announcement: Outcome of Board Meeting under Regulation 30 of SEBI LODR

Audit Opinion:

Unmodified opinion expressed by statutory auditors DMKH & Co. on both standalone and consolidated financial results for the financial year ended 31st March 2026.

Key Financial Highlights [₹ in Lakhs]:

Standalone Results:

Quarter Ended 31-Mar-26:

  • Revenue from Operations: ₹2,020.95 (vs ₹2,331.67 in Q4 FY25, -13.3% YoY)
  • Total Income: ₹2,064.78
  • Net Profit: ₹61.43 (vs ₹137.23 in Q4 FY25, -55.2% YoY)
  • EPS: ₹0.21

Year Ended 31-Mar-26:

  • Revenue from Operations: ₹8,573.84 (vs ₹8,255.68 in FY25, +3.9% YoY)
  • Total Income: ₹8,690.89
  • Net Profit: ₹580.50 (vs ₹305.22 in FY25, +90.3% YoY)
  • EPS: ₹1.97 (vs ₹1.14 in FY25)
  • Other Equity: ₹9,138.68 (vs ₹8,561.25 in FY25)
  • Cash and Cash Equivalents: ₹658.79 (vs ₹4.34 in FY25)
  • Total Debt: ₹727.76 (Borrowings: ₹119.06 non-current + ₹608.70 current)

Consolidated Results:

Quarter Ended 31-Mar-26:

  • Revenue from Operations: ₹2,020.95
  • Total Income: ₹2,064.78
  • Net Profit: ₹152.30 (vs loss of ₹145.80 in Q4 FY25)
  • EPS: ₹0.52

Year Ended 31-Mar-26:

  • Revenue from Operations: ₹8,573.84
  • Total Income: ₹8,690.89
  • Net Profit: ₹2,458.35 (vs loss of ₹996.70 in FY25)
  • EPS: ₹8.35 (vs loss of ₹3.72 in FY25)
  • Other Equity: ₹9,319.99 (vs ₹6,864.71 in FY25)
  • Cash and Cash Equivers: ₹658.79

Segment-wise Performance [₹ in Lakhs]:

The company operates through two reportable segments:

Trading Segment:

  • FY26 Revenue: ₹286.58 (vs ₹242.72 in FY25)
  • FY26 Segment Result: Loss of ₹6.38 (vs profit of ₹10.08 in FY25)

Manufacturing Segment:

  • FY26 Revenue: ₹8,287.26 (vs ₹8,012.96 in FY25)
  • FY26 Segment Result: Profit of ₹694.26 (vs ₹441.58 in FY25)

Corporate Actions:

No dividend declarations, share splits, bonus issues, buybacks, or capital raising activities announced.

Other Significant Information:

  • The company issued 32,10,510 equity shares at ₹141.50 per share (face value ₹10 + premium ₹131.50) on preferential basis during previous year
  • Jointly controlled entity Brooks Steriscience Limited recorded revenue of ₹12,791.68 lakhs with licensing income & profit share of ₹5,996.64 lakhs, resulting in PAT of ₹3,832.35 lakhs
  • Company's share in joint venture profit: ₹1,877.85 lakhs for FY26
  • Taxable income absorbed by carried forward tax losses from earlier years
  • No deferred tax assets recognized on brought forward tax losses
  • The numbers for quarter ended March 31, 2026 are balancing figures between audited full year and published reviewed nine months numbers